Stalled on tirzepatide? 8 clinical reasons and what to do

The short answer: most "stalls" have a clinical explanation

If you are taking compounded tirzepatide and the scale stops moving, you are not alone — and in most cases there is a specific, fixable reason. Across the published trials and clinical experience with compounded GLP-1 patients, eight causes account for the majority of "I am not losing weight on tirzepatide" complaints. Six of them are situational and reversible. One is a normal mid-treatment plateau. Only one — true non-response — is rare and structural.

This guide walks through all eight in clinical priority order. Compounded tirzepatide is prepared by US-licensed 503A pharmacies under a patient-specific prescription. It is not FDA-approved, has not been independently evaluated in clinical trials, and is not therapeutically equivalent to FDA-approved Mounjaro® or Zepbound®. All efficacy numbers cited below come from the FDA-approved branded product trials. Individual results vary substantially.

Cause #1: You are still in titration (the most common reason)

The tirzepatide titration schedule used in the SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) starts at 2.5mg weekly for the first four weeks. This 2.5mg dose is explicitly NOT a therapeutic dose for weight loss. It exists only to let your body adapt to GLP-1 and GIP receptor activation before you reach a dose where meaningful fat loss occurs.

The practical implication: if you are in weeks 1-4 of treatment and frustrated that the scale has not moved much, you are almost certainly responding normally. Most patients see only 1-3% body weight reduction by the end of week 4 on the 2.5mg starter. Real movement begins between weeks 5-8 once the 5mg therapeutic dose is reached, and accelerates further at 7.5-10mg around weeks 12-16.

If you are 8-16 weeks into treatment but still on a low dose because of side-effect tolerability concerns, talk to your provider about a slower titration with anti-nausea support rather than staying at a sub-therapeutic dose indefinitely. Staying long-term at 2.5mg or even 5mg is the single most common reason patients report disappointing results.

• Weeks 1-4 at 2.5mg: titration only — not expected to drive meaningful loss
• Weeks 5-8 at 5mg: first therapeutic dose — appetite suppression typically becomes obvious
• Weeks 9-16 at 7.5-10mg: most patients hit their first 5-8% body-weight loss
• Weeks 17+ at 10-15mg: maintenance / max-effect range

Cause #2: A normal mid-treatment plateau (months 3-6)

The second most common reason for a tirzepatide stall is the body adapting to its new lower energy intake — a real, well-characterized physiological response, not a failure of the medication. As body weight decreases, basal metabolic rate decreases somewhat (less mass to maintain), and the body also down-regulates non-exercise activity thermogenesis (NEAT) — fidgeting, posture, spontaneous movement. Together these changes shrink your daily calorie burn.

In the SURMOUNT-1 data, the weight-loss curve is not linear. Most patients see steepest loss in months 2-4, then a noticeable slowing through months 5-7, before another acceleration into month 9+ if adherence and lifestyle hold. A 4-8 week plateau in this window is the rule, not the exception. It is not a sign the medication has stopped working.

What actually helps during a plateau: continuing the medication at the current effective dose, prioritizing strength training (preserves lean mass and prevents metabolic adaptation), recommitting to protein at 0.7-1.0g per pound of target body weight, auditing portion drift, and giving the plateau 6-8 weeks before deciding it represents true non-response.

Cause #3: Calorie creep is undoing the medication's appetite suppression

Tirzepatide reduces appetite and cravings — but it does not enforce a calorie deficit. Patients who lose 8-12% of body weight in the first 4-5 months sometimes find that, by months 6-9, the appetite suppression no longer feels as strong. The body adjusts. Portions creep back up. Snacks return. The 200-400 calorie deficit that was effortless becomes harder to maintain unconsciously.

This is the second-most-frequent "real" cause of a stall (behind the legitimate metabolic plateau). It is reversible with a deliberate audit:

• Track everything you eat for 3-7 days using a tool like Cronometer or MyFitnessPal — most patients undercount intake by 20-30% from memory
• Cross-check liquid calories (sweetened coffee drinks, alcohol, juices) — these often slip in unmeasured
• Look at portion sizes vs the appetite signals you used to follow — if you were satisfied with 4oz of protein in month 2 and you now eat 8oz, that is a real ~300 calorie shift
• Note eating-window drift: if you stopped breakfast at month 2 and added it back at month 6, that is often a 300-500 calorie change

Cause #4: Inadequate protein is masking fat loss with muscle loss

This one shows up on the scale as a stall, but it is actually a body-composition problem. When patients on GLP-1 medications eat reduced calories without prioritizing protein, the body cannibalizes lean muscle alongside fat. The scale weight loss continues but the patient loses energy, gets weaker, and may eventually plateau because metabolic rate drops faster than expected for the amount of fat lost.

The protein target most clinicians use for patients on GLP-1 therapy: 0.7-1.0 grams of protein per pound of target body weight, distributed across 3-4 meals. For a patient targeting 160 lbs, that is roughly 112-160g of protein daily — meaningfully higher than what people on appetite-suppressing medications often eat by default.

Resistance training 2-3x per week with this protein intake substantially blunts muscle loss during a calorie deficit. Without it, lean-mass loss on GLP-1 therapy can reach 25-30% of total weight lost, which is high. With protein + resistance training, that fraction drops closer to 15%.

Cause #5: Sleep, alcohol, and stress are blunting the medication

Tirzepatide acts on appetite, glucose handling, and insulin sensitivity — all systems that are directly affected by sleep, alcohol, and chronic stress. Patients with consistent 5-6 hours of sleep per night typically experience higher ghrelin (hunger hormone), lower leptin (satiety hormone), worse insulin sensitivity, and stronger cravings — all of which work against the medication's mechanism.

Alcohol is particularly disruptive on GLP-1 therapy. It provides 7 calories per gram (more than carbohydrates or protein), impairs fat oxidation while it is being metabolized, disrupts sleep quality even at moderate doses, and tends to drive higher-calorie food choices in the same evening. Patients who stall on tirzepatide while consistently drinking 3-7 drinks per week often see weight loss resume within 2-3 weeks of stopping or significantly reducing.

Chronic stress elevates cortisol, which both blunts fat loss in the abdominal region and increases cravings for high-calorie palatable foods. It is not a willpower failure — it is a hormonal effect. Patients in high-stress jobs or life situations may need to deliberately add stress-management interventions (sleep hygiene, brief daily walks, breath work, time off devices) for the medication to do its full job.

Cause #6: A medication or medical condition is blunting your response

Several common medications and conditions reduce tirzepatide's effectiveness in ways that are not always obvious to patients:

Cause #7: True non-response (rare, but real)

A small percentage of patients are genuine non-responders to tirzepatide. In the SURMOUNT-1 trial, 4-9% of participants on therapeutic doses lost less than 5% of their starting body weight by week 72. The exact biological reasons are still being characterized in the literature — genetic differences in incretin receptor sensitivity, gut microbiome composition, and individual variation in appetite regulation are all hypotheses.

If you have been on a therapeutic dose (10mg or higher) for at least 16-20 weeks, your titration has been clean, your nutrition and sleep are reasonable, and you have lost less than 5% of starting body weight — that is the threshold most providers use to consider treatment options. The typical next steps:

• Re-evaluate compliance with the medication (right injection technique, refrigeration, dose timing)
• Confirm the compounded product was prepared correctly by the pharmacy — your provider can review pharmacy documentation
• Test for undiagnosed conditions that blunt GLP-1 response (thyroid panel, fasting insulin + glucose, vitamin D)
• Consider switching mechanisms — some non-responders to GLP-1 medications respond better to other interventions

Cause #8: A pharmacy quality or product issue

This is uncommon but worth ruling out: compounded medications can vary by pharmacy. Concentration, sterility, and storage requirements all depend on the specific 503A facility preparing the medication. The FDA does not pre-approve compounded drugs for safety, effectiveness, or quality, which is why pharmacy selection matters.

Signs that a product or pharmacy issue may be contributing to a poor response:

• You reached a higher dose (10mg or 15mg) but feel no appetite change at all — this is unusual; most patients feel at least some appetite suppression even at 5mg
• The medication arrived warm, was stored at room temperature for extended periods, or appears cloudy or off-color
• You started feeling appetite suppression on one batch and lost it entirely on the next — batch-to-batch variability points to a compounding issue
• The pharmacy refuses to provide a Certificate of Analysis (COA) or batch documentation when asked

What to actually do next

If you are stalled on compounded tirzepatide, work through this in order before assuming the medication is not working for you:

• 1. Confirm you are on a therapeutic dose (5mg or higher for 8+ weeks). If you are still on the 2.5mg starter dose after 4 weeks, that is the first thing to fix.
• 2. Audit nutrition for 7 days with a tracker — calorie creep and protein deficit explain a large fraction of stalls.
• 3. Audit sleep, alcohol, and stress. Two weeks of 7+ hours of sleep and zero alcohol often unsticks a stall.
• 4. Talk to your provider about thyroid, insulin, and vitamin D testing — undiagnosed conditions are not rare.
• 5. Review all your current medications with your provider for the appetite-stimulating or weight-promoting list above.
• 6. If everything above is clean and you have been at a therapeutic dose 16+ weeks with less than 5% loss, your provider may consider a dose adjustment, mechanism change, or other clinical options.

Cora Health's approach for patients hitting a plateau

Cora Health does not prescribe medication. Cora Health connects patients with licensed providers at Wasef Health, PC, who evaluate each patient and — when clinically appropriate — write a patient-specific prescription. Prescriptions are fulfilled by VialsRx (US-licensed 503A) or Hallandale Pharmacy (PCAB-accredited 503A). Both pharmacies are named publicly so patients can independently verify their credentials.

When Cora patients message their provider about a stall, the typical path is: (a) review the titration history to confirm a therapeutic dose has been reached; (b) review nutrition, sleep, and lifestyle factors; (c) order thyroid + metabolic labs if not done recently; (d) consider a dose increase if tolerability allows. Cora Health does not guarantee weight loss outcomes — compounded medications are not FDA-approved, are not therapeutically equivalent to brand Mounjaro® or Zepbound®, and individual results vary.

• See current Cora Health plan options and pricing: /plans/
• How compounded tirzepatide works (mechanism + dosing): /blog/tirzepatide-how-it-works/
• Tirzepatide side effects + management: /blog/tirzepatide-side-effects/
• Compounded vs brand tirzepatide: /blog/compounded-vs-brand-tirzepatide/

Sources and authoritative references

All weight-loss percentages and dosing data below come from clinical trials of FDA-approved branded tirzepatide. Compounded tirzepatide has not been independently evaluated in clinical trials; this article describes mechanism-based expectations and clinical experience, not trial efficacy of compounded products.

• New England Journal of Medicine — SURMOUNT-1 (Jastreboff et al., 2022); 22.5% mean weight loss at FDA-approved 15mg tirzepatide over 72 weeks: nejm.org/doi/full/10.1056/NEJMoa2206038
• New England Journal of Medicine — SURMOUNT-5 (2025); head-to-head FDA-approved tirzepatide vs semaglutide showing ~20.2% vs ~13.7% mean weight loss
• CDC — Adult Obesity Facts (41.9% US adult obesity prevalence, NHANES 2017–March 2020): cdc.gov/obesity/adult-obesity-facts
• FDA — Compounding and the FDA: Questions and Answers: fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
• FDA — Warning Letters database (telehealth GLP-1 enforcement activity 2025-2026): fda.gov warning letters
• LegitScript — Independent verification of Cora Health certification status: legitscript.com/websites/?checker_keywords=trycora.io